Gilead Sciences (GILD -2.85%) didn't have a bad first quarter, but investors didn't find it inspiring either. After publishing its earnings report after market close Thursday, the company saw its share price decline in excess of 2% the following day. That contrasted unfavorably with the 0.6% rise of the S&P 500 index that trading session.Flat sales, but a dramatic flip on the bottom lineFor the period, Gilead's revenue clocked in at $6.67 billion, essentially flat over the same quarter of 2024. The company ...